- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00311675
St. Jude Open Label H5 Trial
26. August 2010 aktualisiert von: National Institute of Allergy and Infectious Diseases (NIAID)
A Single Center, Open-Label, Phase I/II Study of Two 90-µg Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Adult Subjects
The purpose of this study is to see how antibodies (proteins that fight infection) are made after you receive the new H5N1 flu vaccine.
The new H5N1 vaccine will be given to 50 healthy adult lab workers, aged 18 years and older.
Subjects will receive two 90mcg injections (shots in the arm) of the vaccine about 1 month apart.
Subjects will maintain a memory aid to record oral temperature and any response to the vaccine for 7 days after each immunization.
Subjects will be contacted by telephone 1 to 3 days after vaccination.
They will return to the clinic on Day 7. Blood will be drawn before each vaccination and on Days 56 and 180.
Subjects may be involved in the study for about 6 months.
It is anticipated that the vaccine will provide safe protection against influenza H5N1.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The purpose of this open-label, phase I/II study is to investigate the safety and immunogenicity of two 90-mcg doses of intramuscular inactivated influenza A/H5N1 vaccine in healthy adults, aged 18 years and older.
Subjects will receive 2 doses of the vaccine separated by approximately 28 days.
Subjects will maintain a memory aid to record oral temperature and systemic and local adverse events (AEs) for 7 days after each immunization.
Subjects will be contacted by telephone 1 to 3 days after vaccination (approximately Day 2) to assess concomitant medications and the occurrence of AEs, and they will return to the clinic on Day 7 for AE and concomitant medication assessment, a targeted physical examination (if indicated), and review of the memory aid.
Serum for immunogenicity evaluations will be obtained prior to the first vaccination (Day 0) and prior to the second vaccination (at Day 28), and on Days 56 and 180.
Primary objectives are to determine the safety of subvirion inactivated A/H5N1 vaccine in healthy adults and to determine the immunogenicity of subvirion inactivated H5N1 vaccine in healthy adults approximately 1 month following receipt of each of two 90 mcg doses of vaccine.
The secondary objective is to evaluate immunogenicity and the percent of subjects responding approximately 1 and 7 months after the first vaccination.
Primary endpoints are: AE or serious adverse event information (solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessment); geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers 28 days after receipt of second dose of the vaccine; and GMT and frequency of 4-fold or greater increases in serum hemagglutination inhibition (HAI) antibody titers against the influenza A/H5N1 virus 28 days after receipt of the second dose of the vaccine.
The secondary endpoints are GMT and frequency of 4-fold or greater increases in neutralizing antibody titers in each group 1 month and 7 months after receipt of the first dose of vaccine; GMT and frequency of 4-fold or greater increases in serum hemagglutination inhibition (HAI) antibody titers in each group 1 month and 7 months after receipt of the first dose of vaccine; and development of serum antibody responses against antigenically drifted variants of H5N1 influenza viruses.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
35
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 31805
- St. Jude Children's Research Hospital
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Laboratory personal with potential exposure to live H5N1 viruses.
- Male or nonpregnant female (as indicated by a negative urine pregnancy test prior to each dose of vaccine), aged 18 years and older.
- Women of childbearing potential who are at risk of becoming pregnant must agree to practice adequate contraception (i.e., barrier method, abstinence, and licensed hormonal methods) for the entire study period.
- Is in good health, as determined by vital signs (pulse, blood pressure, oral temperature), medical history, and a targeted physical examination based on medical history.
- Able to understand and comply with planned study procedures.
- Provides informed consent prior to any study procedures and is available for all study visits.
Exclusion Criteria:
- Has a known allergy to eggs or other components of the vaccine.
- Has a known allergy or sensitivity to latex (in the stopper).
- Has a positive urine pregnancy test prior to vaccination (if female of childbearing potential) or women who are breastfeeding.
- Is undergoing immunosuppression as a result of an underlying illness or treatment.
- Has an active neoplastic disease or a history of any hematologic malignancy.
- Is using oral or parenteral steroids, high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs.
- Has a history of receiving immunoglobulin or other blood product within the 3 months prior to enrollment in this study.
- Has an acute illness, including an oral temperature greater than 100.4 degrees F, within 1 week of vaccination.
- Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to enrollment in this study, or expects to receive an experimental agent during the 6-month study period.
- Has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: 1
|
Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA.
Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Adverse event (AE) or serious AE information (solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessment).
Zeitfenster: 1 - 3 days after each vaccination to review any AEs and SAEs; approximately 1 week after each vaccination review any AEs and collect for 28 days following the 2nd dose of vaccine. SAEs will be collected throughout the study through day 180.
|
1 - 3 days after each vaccination to review any AEs and SAEs; approximately 1 week after each vaccination review any AEs and collect for 28 days following the 2nd dose of vaccine. SAEs will be collected throughout the study through day 180.
|
Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers.
Zeitfenster: 28 days after receipt of 2nd dose of vaccine.
|
28 days after receipt of 2nd dose of vaccine.
|
Geometric mean titer (GMT) and frequency of 4-fold or greater increases in serum hemagglutination inhibition (HAI) antibody titers against the influenza A/H5N1 virus.
Zeitfenster: 28 days after receipt of 2nd dose of vaccine.
|
28 days after receipt of 2nd dose of vaccine.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers in each group.
Zeitfenster: 1 month and 7 months after receipt of the first dose of vaccine.
|
1 month and 7 months after receipt of the first dose of vaccine.
|
Geometric mean titer (GMT) and frequency of 4-fold or greater increases in serum hemagglutination inhibition (HAI) antibody titers in each group.
Zeitfenster: 1 month and 7 months after receipt of the first dose of vaccine.
|
1 month and 7 months after receipt of the first dose of vaccine.
|
Development of serum antibody responses against antigenically drifted variants of H5N1 influenza viruses.
Zeitfenster: Serum for immunogenicity evaluations will be obtained prior to the 1st vaccination (day 0) and prior to the 2nd vaccination (day 28), and on days 56 and 180.
|
Serum for immunogenicity evaluations will be obtained prior to the 1st vaccination (day 0) and prior to the 2nd vaccination (day 28), and on days 56 and 180.
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. April 2006
Primärer Abschluss (Tatsächlich)
1. Dezember 2006
Studienabschluss (Tatsächlich)
1. Dezember 2006
Studienanmeldedaten
Zuerst eingereicht
5. April 2006
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
5. April 2006
Zuerst gepostet (Schätzen)
6. April 2006
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
27. August 2010
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
26. August 2010
Zuletzt verifiziert
1. Juli 2008
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 05-0130
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
-
National Institute of Allergy and Infectious Diseases...Abgeschlossen
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenGrippeVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...Abgeschlossen
-
Emergent BioSolutionsAbgeschlossenGrippe | VogelgrippeVereinigte Staaten
-
Sanofi Pasteur, a Sanofi CompanyAbgeschlossenDengue-Fieber | Hämorrhagisches Dengue-Fieber | Dengue-Virus | Dengue-ErkrankungenSingapur
-
GlaxoSmithKlineBiological E. LimitedRekrutierung
-
GlaxoSmithKlineRekrutierung
-
GlaxoSmithKlineAbgeschlossenMasern; Mumps; Röteln | Masern-Mumps-Röteln-ImpfstoffVereinigte Staaten, Finnland, Taiwan, Estland, Puerto Rico